TORONTO, March 01, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive“) (TSX-V:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel cannabinoid solutions, and Ehave, Inc. (“Ehave”) (OTCQB:EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, are pleased to announce that they have entered into a collaboration agreement to enable enhanced patient and clinical research data management for Revive’s research initiatives involving medical cannabis for the treatment of liver diseases.
The collaboration agreement will leverage Ehave’s core expertise in health informatics through its Ehave Connect platform. Revive will integrate the Ehave Connect solution of diagnostic and treatment tools with its ongoing research initiatives in liver disease to improve the lives of patients. Ehave Connect will collect and integrate patient data from clinical systems, licensed health surveys, and Ehave’s own patient- and clinician-reported outcome applications, empowering users with an
... read more at: https://globenewswire.com/news-release/2018/03/01/1402039/0/en/Revive-Therapeutics-and-Ehave-Enter-Into-Patient-Research-Data-Collaboration-Agreement-for-Medical-Cannabis-Liver-Disease-Program.html